Abstracts tagged "giant cell arteritis and ultrasound"

Abstract Number: 2784 • 2018 ACR/ARHP Annual Meeting
Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis
Augustin Lecler¹, Thomas Sené², Herve Picard³, Tifenn Leturcq², Kevin Zuber³, Frederique Charbonneau¹, Catherine Vignal-Clermont⁴ and Gaelle Clavel², ¹Department of Radiology, Fondation Ophtalmologique A. de Rothschild, Paris, France, ²Internal Medecine, Fondation Ophtalmologique A. de Rothschild, Paris, France, ³Clinical Research Unit, Fondation Ophtalmologique A. de Rothschild, Paris, France, ⁴Ophtalmology, Fondation Ophtalmologique A. de Rothschild, Paris, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in patient over 50 years of age. It is a medical emergency as it…
Abstract Number: 893 • 2016 ACR/ARHP Annual Meeting
Preliminary Results of a Multi Modal Imaging Study Suggests a Better Accuracy for the Diagnosis of Giant Cell Arteritis
Augustin Lecler¹, Samuel Bidot², Frederique Charbonneau¹, Sabine Derrien², Herve Picard³ and Gaelle Clavel⁴, ¹Department of Radiology, Fondation Ophtalmologique A. de Rothschild, Paris, France, ²Department of Ophthalmology, Fondation Ophtalmologique A. de Rothschild, Paris, France, ³Clinical Research Unit, Fondation Ophtalmologique A. de Rothschild, Paris, France, ⁴Department of Internal Medecine, Fondation Ophtalmologique A. de Rothschild, Paris, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in patient over 50 years of age. It is a medical emergency as it…
Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta^5,6, Andreas P Diamantopoulos⁷, Wulf Forrester-Barker⁸, William Hamilton⁹, Shauna Masters¹⁰, Brendan McDonald¹¹, Eugene McNally⁸, Colin T. Pease¹², Jennifer Piper⁸, John Salmon¹³, Allan Wailoo², Konrad Wolfe¹⁴, Andrew Hutchings¹⁵ and TABUL Study group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Southend University Hospital, Essex, United Kingdom, ⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁹Primary Care, University of Exeter, Exeter, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹¹Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹²Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹³Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹⁴Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁵Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…
Abstract Number: 788 • 2014 ACR/ARHP Annual Meeting
Fast-Track Diagnostic Procedure for Giant Cell Arteritis
Alojzija Hočevar¹, Ziga Rotar² and Matija Tomsic³, ¹Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose Giant cell arteritis (GCA) represents the most common primary vasculitis among adults aged 50 years or above. Recently, the national annual incidence rate in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].